01 Increasing Adoption of Multi-Biomarker Testing Platforms The companion diagnostics market is shifting toward broader testing platforms capable of identifying multiple biomarkers from a single patient sample. This transition is being driven by the growing number of targeted therapies and the need to evaluate several molecular alterations during treatment selection. Multi-biomarker testing can reduce the need for repeated individual assays while helping clinicians identify eligible patients across multiple therapeutic pathways. This shift is increasing the importance of comprehensive molecular profiling capabilities in precision medicine. In May 2026, the U.S. Food and Drug Administration expanded the approved companion diagnostic indications for FoundationOne CDx to detect PIK3CA mutations in advanced or metastatic breast cancer and HRR gene alterations in metastatic castration-resistant prostate cancer, demonstrating the expanding use of broad molecular panels across multiple targeted treatments.
02 Growing Shift Toward Liquid Biopsy-Based Companion Diagnostics The market is increasingly incorporating liquid biopsy approaches that identify treatment-relevant biomarkers from blood samples rather than relying exclusively on tissue biopsies. Liquid-based testing can provide a less invasive method for detecting genomic alterations and can be particularly valuable when tissue samples are limited or difficult to obtain. Continued development of circulating tumor DNA testing is therefore expanding the role of blood-based companion diagnostics in precision oncology. In May 2026, the U.S. Food and Drug Administration expanded companion diagnostic indications for multiple plasma-based assays, including testing for ESR1 mutations in breast cancer and several genomic alterations in other cancers, reinforcing the growing clinical use of liquid biopsy-based companion diagnostics.
01 Expansion of Targeted Cancer Therapies Increases Demand for Companion Diagnostics The increasing development of biomarker-targeted cancer therapies is directly expanding demand for companion diagnostics. These tests identify molecular or protein characteristics that help determine whether a patient is likely to benefit from a particular treatment. As pharmaceutical development increasingly focuses on biomarker-defined patient populations, diagnostic testing becomes an integral part of treatment selection and supports the expansion of the companion diagnostics market.
02 Growing Precision Medicine Adoption Supports Biomarker Testing Healthcare systems are increasingly using molecular and biomarker information to guide treatment selection rather than relying solely on disease type or conventional clinical characteristics. Companion diagnostics provide the testing infrastructure required to identify relevant patient subgroups, supporting more targeted treatment strategies and increasing demand for molecular diagnostic technologies.
01 High Development Costs Increase the Financial Burden of Companion Diagnostics Companion diagnostics often require analytical validation, clinical validation, regulatory submissions, laboratory infrastructure, and coordination with therapeutic development programs. When diagnostic and drug development must progress together, delays or changes in the therapeutic program can increase the financial and operational burden associated with the diagnostic. These requirements can restrict participation among smaller diagnostic developers.
02 Limited Access to Comprehensive Biomarker Testing Restricts Adoption The effectiveness of companion diagnostics depends on access to appropriate testing laboratories, molecular pathology expertise, validated assays, and healthcare infrastructure. Regions with limited diagnostic capacity may struggle to implement sophisticated biomarker testing, restricting the number of patients who can be accurately matched with targeted therapies.
01 Expansion of Liquid Biopsy Applications Creates New Diagnostic Opportunities The development of blood-based biomarker testing creates opportunities to expand companion diagnostics into situations where tissue samples are unavailable, insufficient, or difficult to obtain. Liquid biopsy can support repeated molecular assessment and may enable identification of genomic changes during disease progression, creating additional applications for companion diagnostic developers.
02 Expansion Into Non-Oncology Therapeutics Creates Additional Market Potential Although oncology remains the primary application area, companion diagnostic technologies can also support treatment selection in other therapeutic fields where patient response depends on specific biological characteristics. Expanding biomarker research in autoimmune, infectious, neurological, and other diseases creates opportunities for diagnostic developers to establish new therapeutic-testing combinations.
01 Tumor Heterogeneity Can Reduce the Reliability of Biomarker-Based Treatment Selection Cancer cells can differ substantially within the same tumor and can evolve during disease progression. This biological heterogeneity can make it difficult for a single tissue sample to accurately represent the full molecular profile of a patient's disease. As a result, companion diagnostic developers must account for variations in biomarker expression and genomic alterations when establishing test performance.
02 Regulatory Coordination Between Diagnostics and Therapeutics Can Delay Commercialization Companion diagnostics frequently require coordination between diagnostic development and therapeutic development, creating dependencies between two regulatory pathways. Changes in clinical trial design, therapeutic indications, biomarker definitions, or diagnostic performance requirements can increase development complexity and extend commercialization timelines.
March 2026 Roche Diagnostics expanded its companion diagnostics portfolio with advanced biomarker testing solutions supporting personalized oncology treatments and targeted therapy selection.
January 2026 Agilent Technologies expanded its companion diagnostics capabilities with enhanced pathology and molecular testing solutions designed to support precision medicine workflows.
November 2025 Thermo Fisher Scientific expanded its precision medicine portfolio with next-generation sequencing-based companion diagnostic solutions for oncology applications.
September 2025 QIAGEN expanded its molecular diagnostics portfolio with biomarker testing solutions supporting targeted cancer therapies and personalized treatment decisions.